Are there antibody-drug conjugates approved for Inflammatory Breast Cancer

Antibody-Drug Conjugates (ADCs) for Inflammatory Breast Cancer

Yes, antibody-drug conjugates are treatment options for inflammatory breast cancer (IBC), though their use depends on your specific tumor characteristics—particularly whether your cancer is HER2-positive or HER2-negative.

How ADCs Work

An antibody-drug conjugate is a targeted therapy that works like a "smart bomb." It combines:

• An antibody (a protein that recognizes specific markers on cancer cells)
• A chemotherapy drug attached to it

The antibody finds and attaches to a specific protein on cancer cell surfaces, then enters the cell and releases the chemotherapy directly inside. This approach aims to deliver stronger cancer-fighting power while potentially reducing damage to healthy cells.

ADCs Used in Breast Cancer

According to the NCCN Guidelines for Patients: Inflammatory Breast Cancer (2025), antibody-drug conjugates are among the systemic therapy options. The main ADCs used in breast cancer include:

For HER2-positive IBC:

• Ado-trastuzumab emtansine (Kadcyla) - attaches to HER2
• Fam-trastuzumab deruxtecan-nxki (Enhertu) - attaches to HER2

For HER2-negative IBC:

• Sacituzumab govitecan-hziy (Trodelvy) - attaches to Trop-2 (a different protein found on cancer cells)

Important Context for Your Situation

The NCCN Guidelines emphasize that treatment selection for IBC is based on your tumor's biomarkers—specifically estrogen receptor (ER), progesterone receptor (PR), and HER2 status. Your oncologist will:

1. Review your pathology report to identify which proteins your cancer expresses
2. Determine which ADC (if any) is appropriate for your specific tumor type
3. Consider whether ADCs fit into your overall treatment plan (which typically includes chemotherapy before surgery, surgery, and radiation)

Questions to Ask Your Oncology Team

1. Does my tumor express HER2 or Trop-2? (This determines which ADC options are available)
2. Is an ADC recommended as part of my treatment plan? If so, which one and why?
3. How does an ADC fit into my overall treatment sequence? (IBC typically requires systemic therapy first, then surgery, then radiation)
4. What are the side effects I should expect? (Different ADCs have different toxicity profiles)
5. Are there clinical trials available that include ADCs for my specific IBC subtype?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.